HOME ABOUT CONTACT AVAILABLE ISSUES SUBSCRIBE MEDIA & ADS CONFERENCE CALENDAR
LATEST UPDATES » Vol 21, No 06, June 2017 – Advocacies in Support of Rare Disease Patients       » Bayer and NUS Enterprise Announce Winners of Grants4Apps? Singapore Open Innovation Challenge       » Cancer Control Efforts in Vietnam: Interview with Dr Tran Thanh Huong       » China Sets up National Lab Developing Brain-Like AI Technology       » New Womb-Like Invention for Preterm Infants       » World Asthma Day: Managing and Living with Asthma       » Managing Liver Cancer as a Global Health Problem      
EYE ON CHINA
Mab-Venture Biopharma & Thermo Fisher Establish Asia Pacific's First "SmartFactory" for Antibody Drugs

On 20th April 2017, Mab-Venture and Thermo Fisher have formed a strategic cooperation agreement, under which they will jointly establish an antibody drug "SmartFactory" to promote the development of biopharmaceuticals in Asia.

At the 2017 China (Guangdong) & U.S. Investment Cooperation and Communication Meeting held in Guangzhou, Thermo Fisher, the world leader in scientific services, and Mab-Venture Biopharm Co., Ltd. (Mab-Venture), signed a strategic cooperation agreement in the witness of Chunhua Hu: The Secretary of the Guangdong Provincial Party Committee.

The two companies will establish ‘Mab-Venture & Thermo Fisher Scientific Antibody Technology Showcase and Service Center’ at Guangzhou International Bio Island ("Bio Island"). The center will be the first in Asia Pacific and a world leading intelligent antibody plant utilizing SmartFactory. SmartFactory is an automated control solution developed by Thermo, which optimizes plant-wide resource utilization, integrates manufacturing (batch) information, and facilitates training and validation record management for single-use system facilities. Once established, the Center will provide a variety of antibody drug services including Contract Research Organization (CRO) and Contract Manufacturing Organization (CMO) services.

Mab-Venture and Thermo will collaborate to bring the world's leading solution to China to achieve the goal of "one place", "one bottle of medicine". The agreement will promote local biopharmaceutical companies (especially CROs & CMOs) to maintain product quality and compliance, while greatly enhancing the speed of R&D and reducing costs, so as to facilitate the rapid development of the whole industry, and ultimately benefit the majority of patients.

The collaboration of Thermo Fisher and Mab-Venture on Guangzhou’s Bio Island will also help further fuel the eco-system and promote Guangdong and China’s biotechnology capabilities. It is also an important milestone in the process of the Guangzhou government strengthening Sino-US ties in science and technology after the signing of a comprehensive strategic cooperation agreement with Thermo in 2016.

"The company is located in various cities in Guangdong and has a solid foundation of cooperation with Guangzhou," said Gianluca Pettiti, president of Thermo Fisher China. "In the 'Bio Island' which also is the 'Accelerated Land' of Innovation, we hope to strengthen ties with local partners in the field of biopharmaceuticals, precision medicine and other areas to bring success and practice the long-term commitment 'rooted in China, serve for China'.”

Dr. George Wang, the founder and CEO of Mab-Venture said, “We will further deepen the strength and competitiveness of a variety of antibody contract development (CRO) and contract manufacturing (CMO) services, which is in line with the vision of the Chinese government to enhance the country’s innovative biologics capabilities. We are delighted to have in-depth cooperation with Thermo, especially by introducing SmartFactory, a new intelligent force to strengthen our industry's leading position. The application of this platform can not only shorten facility construction time, but also reduce production costs, improve overall R&D and manufacturing capabilities, in order to create a biotechnology company committed to the whole industry chain.

Source: Mab-Venture Biopharma

Click here for the complete issue.

NEWS CRUNCH  
news The Seventh International Meeting on Synthetic Biology (SB 7.0)
news Healthcare Sustainability in Asia: Now is the Time to Act — FT Asia Healthcare & Life Sciences Summit 2017
news Philip Morris International and British American Tobacco receive award from PETA science group for AOP developments
PR NEWSWIRE  
Asia Pacific Biotech News
EDITORS' CHOICE  

Lady Ganga: Nilza'S Story
COLUMNS  
Subscribe to APBN E-Newsletter
Find us under 'Others' option to receive APBN e-newsletters thrice a month!

APBN Editorial Calendar 2017
January:
Healthcare Focus: LUNGS
February:
War on CANCER
March:
Get to Know TCM
April:
Diabetes: The Big Picture
May:
The Piece of Your Mind - Brain Health/Science
June:
Advocacies in Support of Rare Disease Patients
July:
Food Science & Technology
August:
Eye Care/ Eye Health
September:
Emerging Infectious Diseases
October:
No. 1 Killer — Heart Diseases
November:
Diseases threatening our Children
December:
Skin Diseases/Allergic Reactions
Editorial calendar is subjected to changes.
MAGAZINE TAGS
About Us
Events
Available issues
Editorial Board
Letters to Editor
Instructions to Authors
Advertise with Us
CONTACT
World Scientific Publishing Co. Pte. Ltd.
5 Toh Tuck Link, Singapore 596224
Tel: 65-6466-5775
Fax: 65-6467-7667
» For Editorial Enquiries:
   biotech_edit@wspc.com or Ms Carmen
» For Subscriptions, Advertisements &
   Media Partnerships Enquiries:
   biotech_ad@wspc.com
Copyright© 2017 World Scientific Publishing Co Pte Ltd  •  Privacy Policy